> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biogen Posts A $0.14 Per-Share Loss On RayThera Deal Charge As Growth Drugs Climb 49%
- URL: https://www.bullished.co/biogen-posts-a-0-14-per-share-loss-on-raythera-deal-charge-as-growth-drugs-climb-49-c62de7e2/
- Published: 2026-10-28T10:21:51.000Z
- Updated: 2026-10-28T15:03:52.000Z
- Description: Revenue rose 11% to $2.8 billion, and the company lifted the low end of its 2026 adjusted EPS outlook to $12.20.
- Author: Matteo Parrino
- Tags: Earnings, BIIB, Industry: Healthcare

[Biogen](https://www.bullished.co/tag/biib/), the biopharmaceutical company focused on neurology, specialized immunology and rare diseases, swung to a [loss of $0.14 per share](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000094/exhibit991-q32026pressrele.htm?ref=bullished.co) in the third quarter, from a $3.17 profit a year earlier, in results released Wednesday. Transaction-related charges drove the loss, while revenue grew 11% to $2.8 billion.

## Growth drugs offset the MS slide

Biogen's growth portfolio brought in $1.26 billion, up 49% from a year earlier and 63% of core pharmaceutical revenue. The quarter was the first full one with the Apellis products, which Biogen bought when the deal closed in May 2026.

Spinraza led rare disease at $461 million, up 23%, and the company said the shift to a high-dose regimen continues to exceed its expectations. Leqembi, recorded by partner Eisai, reached $202 million, up 67%. Syfovre rose 27% to $191 million, and Empaveli rose 92% to $52 million. Skyclarys climbed 34% to $178 million.

Multiple sclerosis revenue fell 13% to $919 million. Vumerity slid 11% to $192 million, which the company blamed mainly on U.S. formulary dynamics. Rare disease revenue rose 27% to $676 million, and biosimilars fell 16% to $166 million.

CEO Christopher A. Viehbacher said the results show that "Biogen has returned to growth."

## Where the loss came from

Adjusted earnings were $2.62 per share, down from $4.81\. The quarter carried $284 million of acquired research, upfront and milestone expense, mostly for the RayThera purchase, against $2 million a year earlier.

Other costs also rose. Research and development spending was $574 million, up from $436 million, and selling, general and administrative costs were $752 million, up from $595 million, both reflecting Apellis. Net interest expense on Apellis debt also weighed on the adjusted figure. The standard-accounting tax rate was negative 128.5% because the RayThera charge is not deductible.

Free cash flow was about $600 million, after roughly $40 million of capital spending. Biogen ended September with about $1.3 billion in cash and about $7.7 billion in debt.

## Guidance and the December readout

Biogen raised the low end of its 2026 adjusted EPS range to $12.20–$13.00, from $12.00–$13.00\. It cited business strength and lower-than-expected Apellis dilution, and still expects revenue to grow by a mid-single-digit percentage.

Top-line data from two late-stage lupus trials of litifilimab are due in the first half of December 2026.

Biogen expects top-line data from both late-stage litifilimab lupus trials, TOPAZ-1 and TOPAZ-2, in the first half of December 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — BIOGEN INC. (BIIB)](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000094/biib-20261028.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991-q32026pressrele.htm — BIOGEN INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000875045/000087504526000094/exhibit991-q32026pressrele.htm?ref=bullished.co) — SEC EDGAR
- [Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?](https://finance.yahoo.com/healthcare/articles/biogen-q3-preview-growth-products-123800609.html?ref=bullished.co) — Yahoo Finance

### More on Biogen

- [Biogen Says Spinraza's Third Quarter Got A One-Time Lift, With Fourth-Quarter Growth Guided To A Mid-Single-Digit Rise](https://www.bullished.co/biogen-says-spinrazas-third-quarter-got-a-one-time-lift-with-fourth-quarter-growth-guided-ce4b517b/)
- [Biogen CEO Says He 'Always Hated' Buying Late-Stage Drugs And Will Chase Early-Stage Deals](https://www.bullished.co/biogen-ceo-says-he-always-hated-buying-late-stage-drugs-and-will-chase-early-stage-deals-b30240d1/)
- [Biogen Swings To A $20.6 Million Quarterly Loss On A $283.8 Million RayThera Charge](https://www.bullished.co/biogen-swings-to-a-20-6-million-quarterly-loss-on-a-283-8-million-raythera-charge-08233730/)

[All Biogen (BIIB) coverage →](https://www.bullished.co/tag/biib/)